Epitope-Based Peptide Vaccine against Glycoprotein G of Nipah Henipavirus Using Immunoinformatics Approaches

Background. Nipah belongs to the genusHenipavirusand theParamyxoviridae family. It is an endemic most commonly foundat South Asia and hasfirst emerged in Malaysia in 1998. Bats are found to be the main reservoir for this virus, causing disease inboth humans and animals. The last outbreak has occurred in May 2018 in Kerala. It is characterized by high pathogenicity andfatality rates which varies from 40% to 70% depending on the severity of the disease and on the availability of adequatehealthcare facilities. Currently, there are no antiviral drugs available for NiV disease and the treatment is just supportive.Clinical presentations for this virus range from asymptomatic infection to fatal encephalitis.Objective. This study is aimed atpredicting an effective epitope-based vaccine against glycoprotein G of Nipah henipavirus, using immunoinformaticsapproaches.Methods and Materials. Glycoprotein G of the Nipah virus sequence was retrieved from NCBI. Differentprediction tools were used to analyze the epitopes, namely, BepiPred-2.0: Sequential B Cell Epitope Predictor for B cell andT cell MHC classes II and I. Then, the proposed peptides were docked using Autodock 4.0 software program.Results andConclusions. The two peptides TVYHCSAVY and FLIDRINWI have showed a very strong binding affinity to MHC class Iand MHC class II alleles. Furthermore, considering the conservancy, the affinity, and the population coverage, the peptideFLIDRINWIT is highly suitable to be utilized to formulate a new vaccine against glycoprotein G of Nipah henipavirus. Anin vivo study for the proposed peptides is also highly recommended

Epitope-Based Peptide Vaccine against Glycoprotein G of Nipah Henipavirus Using Immunoinformatics Approaches

Background. Nipah belongs to the genus Henipavirus and the Paramyxoviridae family. It is an endemic most commonly found at South Asia and has first emerged in Malaysia in 1998. Bats are found to be the main reservoir for this virus, causing disease in both humans and animals. The last outbreak has occurred in May 2018 in Kerala. It is characterized by high pathogenicity and fatality rates which varies from 40% to 70% depending on the severity of the disease and on the availability of adequate healthcare facilities. Currently, there are no antiviral drugs available for NiV disease and the treatment is just supportive. Clinical presentations for this virus range from asymptomatic infection to fatal encephalitis. Objective. This study is aimed at predicting an effective epitope-based vaccine against glycoprotein G of Nipah henipavirus, using immunoinformatics approaches. Methods and Materials. Glycoprotein G of the Nipah virus sequence was retrieved from NCBI. Different prediction tools were used to analyze the epitopes, namely, BepiPred-2.0: Sequential B Cell Epitope Predictor for B cell and T cell MHC classes II and I. Then, the proposed peptides were docked using Autodock 4.0 software program. Results and Conclusions. The two peptides TVYHCSAVY and FLIDRINWI have showed a very strong binding affinity to MHC class I and MHC class II alleles. Furthermore, considering the conservancy, the affinity, and the population coverage, the peptide FLIDRINWIT is highly suitable to be utilized to formulate a new vaccine against glycoprotein G of Nipah henipavirus. An in vivo study for the proposed peptides is also highly recommended